

pDC induce immune tolerance in ovarian cancer

1 **Research article**

2 **Title**

3 **Quantitative and functional alterations of plasmacytoid dendritic**
4 **cells contribute to immune tolerance in ovarian cancer**

5 **Authors**

6 Sana Intidhar Labidi-Galy^{1,2}, Vanja Sisirak², Pierre Meeus⁴, Michael Gobert², Isabelle
7 Treilleux^{2,3}, Agathe Bajard⁵, Jean-Damien Combes⁵, Julien Faget², François Mithieux⁴,
8 Alexandre Cassagnol⁶, Olivier Tredan^{1,2}, Isabelle Durand², Christine Ménétrier-Caux²,
9 Christophe Caux², Jean-Yves Blay^{1,2}, Isabelle Ray-Coquard¹, and Nathalie Bendriss-Vermare²

10

11 **Affiliation**

12 ¹Department of medical oncology, Centre Léon Bérard, 28 rue Laennec Lyon, 69008, France

13 ² Université Lyon 1, ISPB, F-69008 Lyon, France ; INSERM U1052, Centre de Recherche en
14 Cancérologie de Lyon, F-69008 Lyon, France ; Centre Léon Bérard, F-69008 Lyon, France

15 ³Department of pathology, Centre Léon Bérard, 28 rue Laennec Lyon, 69008, France

16 ⁴Department of surgery, Centre Léon Bérard Lyon France, 28 rue Laennec Lyon, 69008,
17 France

18 ⁵Department of biostatistics, Centre Leon Bérard, 28 rue Laennec Lyon, 69008, France

19 ⁶Department of surgery, Infirmierie Protestante, Chemin du Penthod Caluire, 69300, France

20

21 **Running title**

22 pDC induce immune tolerance in ovarian cancer

23

24

pDC induce immune tolerance in ovarian cancer

1 **Key-words**

2 Plasmacytoid dendritic cell, ovarian cancer, immune tolerance, progression-free survival,
3 dysfunction

4

5 **Corresponding author**

6 Sana Intidhar LABIDI-GALY

7 E-mail: labidi@lyon.fnclcc.fr

8 Address: Department of medical oncology, Centre Léon Bérard and Université Lyon 1, ISPB,

9 F-69008 Lyon, France ; INSERM U1052, Centre de Recherche en Cancérologie de Lyon , 28

10 rue Laennec 69008 Lyon, France

11 Tel: + 33 4 78 78 29 38

12 Fax: + 33 4 78 78 27 16

13

14

15 **Paper length**

16 Words: 4778

17 7 figures. 4 supplementary figures and 2 supplementary tables.

18

19 **Paper presented at a meeting**

20 The work was presented in part at the 101st American Association for Cancer Research Annual

21 Meeting 2010, Washington DC. April 17-21, 2010 (Abstract 1910)

22

23

24

pDC induce immune tolerance in ovarian cancer

1 **Abstract**

2 In ovarian carcinoma (OC) the immune system fails to eradicate established tumors partly due to
3 the induction of immune tolerance within tumor microenvironment. In this study, we
4 investigated the contribution of plasmacytoid dendritic cells (pDC) in the establishment of
5 immune tolerance in a cohort of 44 ovarian cancer patients. In the tumor and malignant ascites,
6 CD4+CD123+BDCA2+ pDC were the most abundant dendritic cell subset, however, they were
7 profoundly depleted in peripheral blood. The presence of pDC in primary OC, but not ascites,
8 was an independent prognostic factor associated with early relapse. Following chemotherapy,
9 we observed a partial restoration of blood pDC levels in patients in complete remission. These
10 findings demonstrate preferential recruitment of pDC into tumors where they express a partially
11 mature phenotype that may reflect an in situ activation. Importantly, compared to pDC found in
12 ascites or blood, tumor-associated pDC (TApDC) produced less IFN- α , TNF- α , IL-6, MIP-1 β ,
13 and RANTES in response to toll like receptor stimulation, and alterations in pDC functions were
14 mainly mediated through tumor-derived TNF- α and TGF- β . Unlike ascites-derived pDC,
15 TApDC induced IL-10 production from allogeneic naive CD4+ T lymphocytes, suggesting the
16 existence of a paracrine immunosuppressive loop. Taken together, our findings indicate that
17 both local and systemic dysfunction of pDC play a critical role in the progression of ovarian
18 carcinoma via induction of immune tolerance.

19 219 words

20

pDC induce immune tolerance in ovarian cancer

1 **Introduction**

2 Ovarian cancers (OC) are the leading cause of death from gynaecologic cancers and the fifth
3 most common overall cause of cancer death among women (1). Most women (~75%) present
4 with advanced stage disease, for which the 5 year survival rate is a dismal 30% or less, and has
5 not changed over 3 decades (2). Thus, understanding mechanisms underlying therapeutic
6 success and failure has important clinical relevance: predicting non-response and developing
7 new therapeutic approaches may improve outcome.

8 Plasmacytoid dendritic cells (pDC) are one of two main subsets of human dendritic cells (DC) in
9 blood. PDC are identified as a CD4⁺, CD11c⁻, lineage marker⁻, and HLA-DR⁺ cells that express
10 CD123/IL-3 receptor alpha chain and/or as BDCA2- and BDCA4-expressing cells (3). At steady
11 state, they are circulating in blood and directly enter in lymph nodes through the high
12 endothelial venules (HEV)(4, 5) and are absent from peripheral tissues. PDC are crucial
13 effector cells in antiviral immunity. Indeed, in response to viral stimulation (6) through toll like
14 receptors (TLR) 7 and 9 (7), they produce high amounts of type I IFN (α , β , and ω). PDC link
15 innate and adaptive immune responses by promoting the activation and differentiation of natural
16 killer (NK) cells, B cells, myeloid DC (mDC), and T cells (7-9). Consistent with their antigen
17 presentation capabilities, pDC were also shown to mediate tolerance to allogeneic antigens in
18 cardiac allograft (10), oral antigens (11), and airway allergens (12).

19 Emerging evidence indicates that tumor infiltration by pDC may have clinical importance, as
20 underlined by their identification in tumors including melanoma, head and neck, lung, ovarian
21 and breast cancers (13-15). Several types of cancers are characterized by impaired function and
22 numbers of pDC (13, 16), but correlations of pDC frequency with disease progression in cancer
23 remain poorly studied. Infiltration of primary breast carcinomas by pDC is variable and their
24 presence at high density is associated with poor clinical outcome (17) and their depletion in the
25 blood of pancreatic cancer patients is correlated with reduced survival (18).

pDC induce immune tolerance in ovarian cancer

1 In ovarian cancer, several studies have shown an accumulation of pDC in malignant ascites,
2 with depletion in blood (14, 19, 20). PDC were reported to be attracted into ascites through
3 SDF-1/CXCL12, to produce high amounts of type I IFN in response to TLR ligand (14, 21), and
4 to induce CD8⁺ regulatory T cells which suppress tumor antigen-specific T cells through the
5 production of IL-10 (21). In addition, ascite pDC were shown to favour tumor-angiogenesis *via*
6 the production of TNF- α and IL-8 (20). However, the role of tumor-infiltration by pDC (called
7 tumor-associated pDC (TApDC)) in advanced OC remains to be addressed.

8 In this report, we have characterized the tissue distribution, phenotype and functions of pDC in
9 advanced epithelial ovarian carcinoma and their impact on patients' clinical outcome. Our
10 findings bring new insights into the physiopathology of pDC in the context of ovarian cancer in
11 humans, demonstrating quantitative systemic and local functional alterations of pDC associated
12 with progression.

13

14

15

pDC induce immune tolerance in ovarian cancer

1 **Materials and Methods**

2 **Patients**

3 We studied 44 untreated patients with International Federation of Gynaecology and Obstetrics
4 (FIGO) stage I, II, III, and IV epithelial ovarian carcinomas. All patients gave written, informed
5 consent. The study was approved by local institutional review boards. Biological samples were
6 collected at Centre Leon Bérard, Lyon and other institutions in Rhône-Alpes Region, France.

7 **Preparation of tumors and ascites cell suspensions**

8 We collected fresh solid tumors and malignant ascites aseptically. Cells were harvested from
9 ascites by centrifugation over a Ficoll-Hypaque density gradient. Ovarian tumors samples were
10 minced into small pieces in serum free RPMI medium and digested with collagenase Ia (1
11 $\mu\text{g/ml}$) and DNase I (50 KU/ml) (Sigma Aldrich) for one hour at 37°C with gentle agitation. The
12 resulting cell suspensions were filtered, washed, and resuspended in RPMI 1640 medium
13 (Invitrogen) supplemented with 10 % FCS (Lonza) and antibiotics (complete RPMI) before
14 isolation of mononuclear cells (MNC) by centrifugation over a Ficoll-Hypaque density gradient
15 for further analyses.

16 **Peripheral blood mononuclear cells**

17 Peripheral blood was collected aseptically from healthy donors (HD; n=55) or OC patients
18 (n=44) in a CTAD-coated tube. Peripheral blood mononuclear cells (PBMC) were obtained over
19 a Ficoll-Hypaque density gradient, washed twice, and resuspended in phosphate-buffered saline
20 containing 2% FCS (Lonza) and 0.5 mM EDTA for flow cytometry analysis.

21 ***Ex vivo* mononuclear cell stimulation.**

22 We stimulated MNC from tumors, ascites and peripheral blood from 6 patients and 8 healthy
23 donors (HD) in complete RPMI at 1×10^6 cells per well in duplicate wells with formaldehyde-
24 inactivated influenza (flu) virus (A/Wisconsin/67/05) (generous gift from Aventis Pasteur) and
25 CpG-A/ODN 2336 that were used at 100 HAU/ml and 5 $\mu\text{g/ml}$, respectively in 24-well tissue

pDC induce immune tolerance in ovarian cancer

1 culture plate at 37°C. Cell-culture supernatants were harvested after 18 h and used for cytokines
2 production quantitation by human enzyme-linked immunosorbent assay (ELISA).

3 **PDC purification from blood, tonsils, tumors, and ascites**

4 To isolate pDC from biological samples, CD3⁻, CD8⁻, CD11b⁻, CD14⁻, CD16⁻, CD19⁻, CD20⁻,
5 CD56⁻, Glycophorin A⁻ and EpCAM-expressing cells were depleted using specific antibodies
6 and paramagnetic beads (Invitrogen). PDC from blood and healthy donor tonsils were purified
7 from lineage-negative enriched MNC using the BDCA4 cell isolation kit (Miltenyi Biotec)
8 according to the supplier's instructions. Ovarian tumors or malignant ascites pDC were sorted
9 from lineage-negative enriched MNC using FACS® (FACSVantage SE™ DiVa flow cytometer,
10 BD Bioscience) as CD4⁺CD123⁺ cells using APC anti-CD123 (Biolegend) and PE-Cy5 anti-
11 CD4 (Beckman Coulter). Purity was routinely $\geq 98\%$.

12 **Preparation of ovarian tumors and ascites-derived supernatants**

13 Single-cell suspensions from ovarian tumors and ascites were incubated at a final concentration
14 of 1.5×10^6 cells/ml in complete RPMI in petri dishes. Culture supernatants were collected after
15 48h, filtrated on 0.2 μm , and cryopreserved at -80°C until use.

16 **Culture of ovarian tumor-associated or healthy pDC**

17 Freshly isolated TApDC and ascite pDC were cultured at 5×10^5 cells/ml in 96-well flat-bottom
18 plates in complete RPMI for 24 h in presence of recombinant hIL-3 (Peprotech), formaldehyde-
19 inactivated influenza (flu) virus (A/Wisconsin/67/05) and CpG-A/ODN 2336 that were used at
20 20 ng/ml, 100 HAU/ml, and 5 $\mu\text{g/ml}$, respectively. Freshly isolated healthy blood or tonsil pDC
21 were cultured as previously mentioned in the presence of hIL-3 with or without ovarian tumor
22 (TUMSN) or ascite (ASCSN) supernatants supplied at 25% for 16 h before addition of TLR
23 ligands for another 24 h. Cells and supernatants were harvested after 24 h for TApDC and ascite
24 pDC, and 40 h for healthy pDC culture to analyze cell surface expression of activation markers

pDC induce immune tolerance in ovarian cancer

1 and cell viability (by Propidium Iodide incorporation) by flow cytometry and cytokines
2 production by ELISA.

3 **Flow cytometry analysis**

4 Three-color staining was performed by flow cytometry on a FACScan (BD Bioscience) using
5 isotype-matched controls or monoclonal antibodies and data were analyzed with CellQuest
6 software (BD Bioscience). pDC were identified as CD4⁺CD123⁺BDCA2⁺ cells using FITC anti-
7 BDCA2 (Miltenyi Biotec), PE anti-CD123 (BD Bioscience) and PE-Cy5 anti-CD4 (Beckman
8 Coulter). Myeloid DC (mDC) were identified as Lin⁻CD4⁺CD11c⁺ using FITC conjugated
9 lineage (Lin) cocktail (CD3, CD14, CD16, CD19, CD20 and CD56; BD Bioscience), PE anti-
10 CD11c (BD Bioscience), and PE-Cy5 anti-CD4 (Beckman Coulter) antibodies. CD4 T
11 lymphocytes were identified as CD3⁺CD4⁺ cells using FITC anti-CD3 (BD Bioscience) and PE-
12 Cy5 anti-CD4 antibodies (Beckman Coulter). The phenotype of CD4⁺BDCA2⁺ pDC was
13 analyzed with PE-coupled anti-CD86 (BD Bioscience) and anti-CD40 (Beckman Coulter).
14 monoclonal antibodies. Viability was assessed by Propidium Iodide incorporation. Flow
15 cytometry results are expressed as % positive cells and mean fluorescence intensity (MFI). At
16 least 200,000 gated events/condition were analyzed on the total cell population and 5000 gated
17 events/condition on purified cells.

18 **Allogeneic mixed leucocyte reaction (MLR)**

19 Allogeneic CD4⁺CD45RA⁺ naïve T cells were purified from HD peripheral blood after magnetic
20 depletion using anti-CD8, -CD14, -CD19, -CD16, -CD56, and -glycophorin A antibodies
21 followed by anti-IgG beads (Invitrogen). The purity was routinely > 95%. Highly purified
22 FACS-sorted pDC from ovarian tumors and ascites from the same patients were differentiated
23 by culture in IL-3 (20 ng/ml) for 16 hours and then cultured with responder T cells in a ratio of
24 0;3;11;33;111;333;1,111;3,333 and 10,000 per 100,000 T cells for 96 hours in triplicate in round
25 bottom 96-well plates. Finally, cells were pulsed with 0.5μCi per well [³H]thymidine

pDC induce immune tolerance in ovarian cancer

1 (Amersham Biosciences) and harvested 18 h later. The [3H]thymidine incorporation was
2 assessed by liquid scintillation spectroscopy (Betaplate scintillation counter, Perkin Elmer).
3 Culture supernatants were collected for cytokine analysis by ELISA.

4 **Determination of cytokines production**

5 The ELISA for hIFN- α (Bender MedSystems), hIL-10 (Bender MedSystems), hIFN- γ (Bender
6 MedSystems), and hIP-10/CXCL10 (BD Biosciences) were used according to manufacturer's
7 instructions. Levels of TNF- α , IL-6, IL-8, MIP-1 β , IP-10, RANTES, IL-12p40 and IL-12 p70 in
8 culture supernatants were determined using a Milliplex map, based on the Luminex xMAP
9 technology by Millipore (Billerica, MA).

10 **Statistical analysis**

11 Comparison of independent samples was done by the student's *t* test or non-parametric tests
12 when appropriate. Correlation analysis of the data was performed using the Spearman test. The
13 following clinical variables were collected prospectively: age, Performance Status (PS), stage,
14 debulking surgery, and the presence of macroscopic residual disease. PDC and mDC levels in
15 tumors and ascites were categorized in upper tertile and lower two tertiles.

16 Progression-free survival (PFS) was defined as the time from pathologic diagnosis to
17 progression. PFS was calculated using Kaplan-Meier method. To evaluate the relationship
18 between survival and biological and/or clinical factors, all potential prognostic factors were
19 included in univariate Cox proportional hazard regression models (22). Candidate prognostic
20 factors with a 0.05 level of significance in univariate analysis were then selected for inclusion
21 in the multivariate analysis. Independent prognostic variables of PFS were identified by a Cox
22 regression analysis using a backward selection procedure to adjust the time cohort effect on
23 patient's characteristics. All statistical analyses were performed using SAS software v.9.2 for
24 Microsoft Windows (SAS Institute, Cary, NC). All P values for two-tailed tests were
25 considered significant when $P < 0.05$.

26

pDC induce immune tolerance in ovarian cancer

1 **Results**

2 **Accumulation of pDC in ascites and depletion in the blood**

3 We evaluated the tissue distribution of CD4⁺CD123⁺BDCA2⁺ pDC (3, 23) (Figure S1A) and
4 Lineage⁻CD4⁺CD11c⁺ mDC (Figure S1B) (24) as a fraction of total MNC in 44 patients with
5 previously untreated epithelial ovarian cancers (OC). Patients' characteristics are detailed in
6 Table S1. Consistent with previous investigations (14), the percentage of both pDC and mDC in
7 total PBMC were significantly reduced ($p < 10^{-3}$) in OC patients (mDC median %=0.04, range 0-
8 0.65; pDC median %=0.11, range 0.01-0.98) compared to healthy donors (HD)(mDC median
9 %=0.18, range 0-1.19; pDC median %=0.32, range 0.07-0.78) (Figures 1A and 1B). The
10 depletion of blood pDC tended to be deeper in advanced stages (III/IV) (0.1%) OC patients
11 compared to early stages (I/II) (0.19%), although this did not reach statistical significance
12 ($p=0.09$; Figure 1C). Similar variations according to stage were observed with mDC ($p=0.43$;
13 Figure 1D). These data suggest that pDC are actively recruited from blood to the tumor.

14 In order to document variations in pDC number in blood during treatment, we determined pDC
15 levels in patients at diagnosis (n=44), on therapy i.e. after 4 cycles of chemotherapy (n=12), in
16 complete remission (CR) 3 months after the end of treatment (n=10) and at progression (n=12).
17 We observed partial restoration of blood pDC in most of the patients after 4 cycles of
18 chemotherapy ($p=0.01$; Figure 1E) which was maintained in patients in CR ($p < 10^{-2}$). In contrast,
19 we observed a trend toward decreased pDC levels in patients with progressive disease when
20 compared to those in CR ($p=0.22$). For mDC, we observed significant lower levels in
21 progressive patients when compared to HD ($p < 10^{-3}$; Figure 1F).

22 Concerning their tissue distribution, pDC infiltrated some tumors (median %=0.06, range 0-
23 0.68) and accumulated in the majority of malignant ascites (median %=0.83, range 0.04-2.93;
24 Figure 1A). Indeed, ascites pDC were 7.2-fold higher than patient blood pDC ($p < 10^{-3}$) and 13.8-
25 fold higher than TApDC ($p < 10^{-3}$). MDC were present in malignant ascites (median %=0.06,

pDC induce immune tolerance in ovarian cancer

1 range 0-0.86) but in lower proportions than pDC ($p < 10^{-3}$) while their presence in tumors was
2 scarce (median %=0.01, range 0-0.13; Figure 1B).

3

4 **Correlation of TApDC frequency with poor clinical outcome**

5 The distribution of pDC was skewed with depletion in blood in most of OC patients and
6 accumulation in some tumors and especially in malignant ascites. We questioned the impact of
7 the presence of pDC in tumors and ascites on patients' outcome. We adopted a classification by
8 tertile (33rd percentile) to compare the highest tertile subgroup to all others. To address this
9 question, we analyzed all relevant clinical and pathological information's (Table S1) that were
10 available on the 44 patients. As our study was prospective with a median follow-up of 14
11 months, we centred our analysis on progression free-survival (PFS). In addition to TApDC
12 levels, five clinico-pathological variables (age, stage, PS, debulking surgery, and the presence of
13 residual disease) were analyzed due to their previously described prognostic significance in OC
14 (25). We observed that the subgroup of patients who progressed showed significantly higher
15 levels of TApDC than those in complete remission ($p < 0.05$; Figure 2A). In univariate analysis,
16 the following factors were associated with prolonged PFS: early stage (I-II), debulking surgery,
17 absence of residual tumors and low tumor-infiltration by pDC defined as < 0.1 % of total MNC
18 (Figure 2B and Table S2).

19 In contrast, high levels of ascite pDC had no impact on OC patients' outcome (Figure 2C).
20 When using a cut-off of ascite pDC ≥ 1 % of total MNC (10-fold higher than in tumors), median
21 PFS was estimated to 13.6 months compared to 10.8 months in patients with ascite pDC $< 1\%$
22 (HR=0.94, CI=0.38-2.34, $p=0.89$). To assess whether this effect was specific to pDC or
23 concerned all dendritic cells, we further investigated the impact of mDC accumulation in ascites
24 and tumors on PFS. We did not observe any impact of tumor-Associated mDC (TAmDC) nor
25 ascite mDC on PFS of OC patients (Figures 2D and 2E; Table S2).

pDC induce immune tolerance in ovarian cancer

1 In multivariate analysis, TApDC remained an independent prognostic factor associated with
2 early relapse. Median PFS for patients with the highest tertile of pDC ($\geq 0.1\%$ of total MNC) was
3 9.7 months whereas those with TApDC $< 0.1\%$ showed a median PFS of 18.4 months (HR=7.13,
4 CI=2.02-25.11, $p=0.002$; Figure 2B and Table S2) suggesting that infiltration of ovarian tumor
5 by pDC has a deleterious effect on patients' outcome.

6

7 **Partial phenotypic activation of TApDC**

8 To examine the possibility that tumors alter pDC status, expression levels of markers involved
9 in pDC maturation/activation or in T cell co-stimulation (24) were measured directly *ex vivo*
10 comparing blood, ascite, and tumor-associated pDC from 17 patients. We found that TApDC
11 expressed a semi-mature phenotype with significantly higher levels of CD40 and CD86,
12 compared to ascites and blood pDC, which showed classic immature phenotype (Figure 3).
13 These findings suggest that ovarian tumors induce partial activation of TApDC *in situ*. To assess
14 whether this observation could be explained by the presence of dead cells(26), we investigated
15 by flow cytometry the percentage of dead cells among MNC in ascites and tumors from 13 OC
16 patients identified by Propidium Iodide incorporation. We observed 5 fold higher levels of dead
17 MNC in tumors (median %=20) than ascites (median %=4.94, $p < 10^{-3}$).

18

19 **Full maturation of TApDC and ascites pDC after *in vitro* stimulation**

20 Highly purified pDC from ascites, ovarian tumors, and HD blood were cultured with IL-3 and
21 TLR ligands (TLR-L). Changes in expression levels were determined using paired analysis of
22 expression of CD40 and CD86 before and after stimulation. CD40 and CD86 expression
23 increased following IL-3, CpG-A, and influenza virus (flu) stimulation in both ascite and tumor
24 pDC at higher levels than blood pDC (Figure 4). Interestingly, TApDC seemed to be more
25 prompted than blood and ascite pDC to mature *in vitro* even in the absence of TLR-L as culture

pDC induce immune tolerance in ovarian cancer

1 in IL-3 induced high expression of both activation markers. Another important observation is the
2 acquisition of a fully mature CD40^{high} CD86^{high} phenotype by both ascite pDC and TApDC but
3 not blood pDC in response to CpG-A. These observations were similar to those obtained with
4 Flu virus. Thus, tumor microenvironment seemed to have altered TLR9 response of ascite pDC
5 and TApDC induced by CpG-A. These findings show that both TApDC and ascite pDC
6 conserve their ability to achieve full maturation following *in vitro* TLR stimulation despite an
7 altered phenotype at baseline.

8

9 **Amplification of IL-10 production by T cells in response to TApDC**

10 pDC play an important role as antigen-presenting cell by inducing antitumor CD4⁺ T cell
11 responses (27). We observed significant correlation between TApDC and CD4⁺ T lymphocytes
12 infiltration in tumors ($r^2=0.657$, $p<10^{-3}$; Figure 5A) whereas no significant correlation was
13 observed with mDC ($r^2=0.278$, $p=0.13$). Next, we examined the function of TApDC in priming
14 T cell responses. Freshly FACS-sorted pDC from ascites and ovarian tumors from the same
15 patients (n=2) were used to stimulate naïve allogeneic CD4⁺ T cells purified from HD blood *in*
16 *vitro*. Both TApDC and ascite pDC induced proliferation of allogeneic naïve CD4⁺ T cells in a
17 dose-dependent manner (Figure 5B). Strikingly, TApDC induced strong IL-10 ($p<0.05$)
18 production by primed T cells and slightly higher levels of IFN- γ in comparison to ascite pDC
19 (Figure 5C). These results lead us to propose that TApDC may contribute to create an
20 immunosuppressive environment through the generation of IL-10-producing T cells.

21

22 **Inhibition of IFN- α production in TApDC**

23 The production of IFN- α in response to TLR 7 and 9 ligands represents a key mediator in pDC
24 innate function (28). We compared the capacity of blood pDC from HD (n=12), TApDC and
25 ascite pDC from OC patients (n=5) to produce IFN- α in response to TLR ligands. Consistent

pDC induce immune tolerance in ovarian cancer

1 with a previous report (14), ascite pDC produced high levels of IFN- α in response to TLR7 and
2 9 ligands (Figure 6A). Although not significant, they produce even more IFN- α than HD blood
3 pDC in response to Flu ($p=0.1$; Figure 6A) but not CpG-A ($p=0.54$; Figure 6B). In contrast, we
4 observed a severe inhibition of IFN- α production in TApDC compared to ascite and blood pDC
5 mainly in response to TLR9 (CpG-A) and to a lower extent to TLR7 ligands (flu virus). These
6 results indicate that the capacity of pDC to produce IFN- α was selectively altered at the tumor
7 site.

8 PDC were profoundly depleted from the blood of OC patients preventing their isolation. As
9 pDC is the main cellular source of IFN- α in response to TLR ligands, we compared the capacity
10 of total MNC (adjusted to the percentage of pDC) of blood, ascite, and tumors from the same
11 patients ($n=6$) and PBMC from HD ($n=8$) to produce this cytokine. IFN- α production was
12 reduced in tumor-associated MNC compared to ascite or blood MNC after exposure to CpG-A
13 (Figure 6D) confirming that only pDC into tumor mass are altered for this innate function.
14 Although pDC are severely depleted in OC patient's blood, they are still functional as patients'
15 PBMC produced similar levels of IFN- α in response to TLR ligands than HD (Figures 6C and
16 6D).

17 We further investigated the production of 8 cytokines/chemokines (TNF- α , IL-6, IL-8, IL-
18 12p40, IL-12p70, MIP-1 β , IP-10, and RANTES) by FACS-sorted TApDC and ascite pDC that
19 were activated *in vitro* by TLR ligands (Figures S2A and S2B). We observed, similar to IFN- α ,
20 a significant inhibition of pro-inflammatory cytokines (IL-6 and TNF- α) and chemokines (MIP-
21 1 β and RANTES) production by TApDC mainly in response to TLR9 ligand (Figure S2A). By
22 contrast, there was no significant difference for the production of IL-8 and IP-10 by TLR-
23 activated TApDC and ascite pDC (Figure S2B).

24 Altogether, the substantial differences between TApDC and ascite pDC in term of frequencies,
25 phenotype, response to TLR ligands, and impact on patients' outcome suggest that pDC are

pDC induce immune tolerance in ovarian cancer

1 differentially affected in the microenvironment of ascites and tumors suggesting that malignant
2 ascites do not closely mirror the tumor microenvironment of the tumor mass.

3

4 **Inhibition of IFN- α production of healthy pDC by ovarian tumor-derived supernatants**
5 **mainly through TGF- β and TNF- α dependent mechanism *in vitro***

6 The weak IFN- α production of TApDC compared to ascite and blood pDC suggests that the
7 tumor microenvironment actively and specifically inhibits TApDC ability to produce IFN- α .
8 To decipher the mechanisms involved in TApDC dysfunction, pDC isolated from blood and/or
9 tonsils of HD were preincubated in presence of IL-3 and ovarian tumor-derived supernatants
10 (TUMSN, n=5) for 16 h and then stimulated during 24 h with TLR ligands (flu virus or CpG-
11 A). Most of TUMSN inhibited IFN- α production of pDC to both flu virus (median % of
12 inhibition= 60.8%) and CpGA (median% of inhibition= 53.2%) (Figure 7A). In contrast, IP-10
13 production remained unaffected (Figure 7A) and no effect on pDC viability was detected (data
14 not shown), excluding that the negative effect of TUMSN on IFN- α production by TLR-
15 activated pDC involved induction of cell death. These results suggest that soluble factors
16 present within the tumor environment contribute to the functional inhibition of TLR-activated
17 pDC. Of most importance, supernatants derived from tumors (TUMSN) were more efficient
18 than those derived from ascites (ASCSN) (48 to 67% compared to 14 to 23% of inhibition
19 respectively; $p < 10^{-2}$) to block IFN- α production by CpG-A-activated pDC (Figure S3).

20 We next investigated the involvement of several well-known immunomodulators including
21 TGF- β (29), TNF- α , and IL-10 (30) to inhibit of IFN- α production by pDC. We observed that
22 TUMSN contained significantly higher levels of TNF- α (median=470 pg/ml, range 279-
23 2,503pg/ml) than ASCSN (median=218pg/ml, range 64-476pg/ml; $p=0.03$)(Figure S4A). IL-10
24 was also higher in TUMSN (median=2,900pg/ml, range 263-5,862 pg/ml) than ASCSN
25 (median=1,638pg/ml, range 530-2,864pg/ml) but this difference was not significant ($p=0.07$;

pDC induce immune tolerance in ovarian cancer

1 Figure S4B) whereas active TGF- β 1 was present at similar levels in both TUMSN and ASCSN
2 (Figure S4C).

3 In order to investigate the role of IL-10, TGF- β , and TNF- α in pDC alteration by the tumor
4 microenvironment, we blocked these cytokines in ovarian TUMSN using neutralizing
5 antibodies (Ab). Blocking TNF- α and TGF- β independently, but not IL-10, induced a partial
6 reversion of ovarian TUMSN-mediated inhibitory effect on IFN- α production of healthy pDC
7 (Figure 7B). TUMSN-mediated inhibitory effect on IFN- α production was totally reversed
8 when TNF- α and TGF- β were simultaneously blocked, while blocking IL-10 together with
9 either TNF- α or TGF- β has only minor additional effect. Collectively, these observations
10 demonstrate that the specific inhibitory effect associated to the soluble fraction of the ovarian
11 tumor environment on pDC innate functions is mainly mediated through TGF- β and TNF- α
12 cooperation.

13

pDC induce immune tolerance in ovarian cancer

1 **Discussion**

2 In this prospective study on 44 patients presenting OC and using *ex vivo* analysis, we showed
3 that TApDC are different from ascite and blood pDC in terms of distribution, phenotype, innate
4 and adaptative functions, and impact on patients' outcome. Indeed, pDC accumulate mainly in
5 malignant ascites whereas their frequencies were variable in ovarian tumors. Of most
6 importance, only accumulation of TApDC was an independent prognostic factor associated with
7 early relapse whereas their presence in ascites was not deleterious for patients. The presence of
8 mDC in ascites and tumors had no impact on patients' outcome highlighting the specific
9 pejorative role of pDC in the context of tumor microenvironment.

10 To further investigate the clinical significance of the presence of pDC in tumors and ascites, we
11 performed a systematic comparison of TApDC and ascite pDC. TApDC showed a semi-mature
12 phenotype as illustrated by higher levels of activation molecules CD40 and CD86. This partial
13 activation of TApDC might be due to endogenous danger signals such as self nucleic acids
14 released by dying cells in the tumor microenvironment (26) which were in higher proportions
15 in tumors than ascites. We also observed increased levels of TNF- α in ovarian TUMSN when
16 compared to ASCSN, a cytokine previously shown to induce pDC maturation(31). In addition
17 to their baseline semi-mature phenotype, TApDC were more potent than ascite or blood pDC to
18 mature *in vitro* in response to both TLR-independent and TLR-dependent signals.

19 In contrast, TApDC but not ascite pDC were strongly affected for their capacity to produce
20 IFN- α upon TLR stimulation, in particular in response to CpG-A, a TLR9 ligand known to
21 induce type I IFN secretion in pDC(32). Collectively, these results demonstrated that TApDC
22 seemed to respond to signals by maturing rather than by producing IFN- α , even in response to
23 IFN- α inducers.

24 Moreover, ovarian tumor-derived supernatants blocked specifically IFN- α production by
25 TLRL-activated pDC *in vitro*. These results suggest that soluble factors present in the tumor

pDC induce immune tolerance in ovarian cancer

1 microenvironment are involved in TApDC dysfunction. In this context, we showed that
2 cytokines such as TGF- β and TNF- α detected in ovarian tumor derived-supernatants, were
3 involved in this pDC dysfunction. The inhibitory role of TGF- β is consistent with a previous
4 study showing that increased intra-tumoral IFN- α levels correlates with reduced TGF- β 1 in
5 breast cancer patients (33). Moreover, recent reports in mice and human showed that this
6 cytokine contributes to peyer patches, splenic stromal, and tumor environments mediated
7 inhibition of pDC capacity to produce IFN- α (29, 34, 35).

8 The deleterious prognostic effect of TApDC in ovarian cancer could be related to the alteration
9 of IFN- α production. This cytokine is indeed active against ovarian cancer *in vitro* (36, 37) and
10 *in vivo* (38, 39). Inhibition of IFN- α production by TApDC might confer a selective advantage
11 for ovarian tumors, as IFN- α has direct anti-tumor activities, by inhibiting tumor cell
12 proliferation and neoangiogenesis, but also by promoting immunosurveillance through the
13 activation of B cells, NK cells and macrophages (reviewed in refs. (40)) and inhibiting tumor
14 stem cell-like population (41).

15 In the current study, we observed that both TLRL-activated TApDC and ascite pDC were able
16 to induce CD4⁺ T cell proliferation consistently with the acquisition of a fully mature
17 phenotype. Importantly, T cell proliferation induced by TApDC correlated with high IL-10
18 production, confirming the role of TApDC in inducing immune tolerance in OC. Taken
19 together, the differences observed between TApDC and ascite pDC suggest that the role of
20 these immune cells are different and possibly opposite according to the tissue. PDC play a pro-
21 inflammatory role in malignant ascites, whereas they are immunosuppressive in tumors. IFN- α
22 produced primarily from pDC, in addition to having direct antitumoral activity (36, 37),
23 provides an important signal for T helper precursor differentiation in favour of a T helper type
24 1 immune response (42).The dramatically decreased secretion of IFN- α by TApDC associated
25 with IL-10 T cell response would have serious consequences on the induction of efficient anti-

pDC induce immune tolerance in ovarian cancer

1 tumoral immune response and explain the deleterious impact of the presence of pDC into
2 tumors. Therefore, tumors may deregulate immunity by attracting and manipulating pDC
3 behaviour.

4 Our data also clearly demonstrate that malignant ascites could not serve as a model for tumor
5 microenvironment in the context of OC. Indeed, TApDC and ascite pDC from OC patients have
6 clearly distinct phenotype, functions, and impact on survival. Our observations are in agreement
7 with the work published by Zou et al. (14, 21) showing that pDC isolated from malignant ascites
8 are functional in terms of IFN- α production. We further provide here novel information showing
9 that the accumulation of pDC in ascites (up to 10-fold higher than in tumors) had no impact on
10 patients' outcome whereas their presence in tumors was deleterious. Moreover, we showed that
11 TApDC were strongly inhibited for their innate response. Thus, functional inhibition of TApDC
12 is strictly dependent on ovarian tumor microenvironment.

13 In our study, we found that blood pDC and mDC were significantly decreased compared to
14 healthy donors, consistent with prior studies in breast (13) and pancreatic cancer (18) patients.
15 This imbalance in the circulating pDC pool is not just exclusively a finding in cancers, but is
16 also observed in patients with autoimmune diseases, such as systemic lupus erythematosus (43)
17 and in chronic HIV infections (44, 45). Importantly, during primary HIV infection, numbers of
18 blood pDC and levels of IFN- α production have been shown to be severely reduced, leading to
19 speculation that HIV disease progression may result in part from the failure of pDC to limit viral
20 replication (45-47). Upon initiation of effective antiretroviral therapy in HIV-infected
21 individuals, the levels of pDC have been shown to partially recover (48, 49).

22 We reported in this work several similarities between OC patients and HIV patients. Indeed, we
23 observed severe reduction in blood pDC in patients with advanced stages OC, similarly to HIV
24 patients (44, 45, 50), in comparison to those with early stages, and to healthy donors. We have
25 also shown severe alteration of IFN- α production in TApDC in comparison to HD blood pDC in

pDC induce immune tolerance in ovarian cancer

1 response to TLR ligands. Similarly to HIV patients undergoing antiretroviral therapy (48), levels
2 of blood pDC partially recovered in patients undergoing chemotherapy or in complete remission
3 whereas there was a trend toward decrease levels in patients with progressive disease. Taken
4 together, these data suggest that the solid tumors exert systemic modulatory effects on the
5 immune system, in addition to their effects in the tumor microenvironment. These similarities
6 observed between HIV and ovarian cancer patients suggest similar mechanisms implicated in
7 the disturbance of blood pDC homeostasis in both diseases.

8 To our knowledge, this work represents the first systematic comparison of pDC phenotype and
9 function in blood, ascites, and tumors from cancer patients. We showed that pDC's functional
10 alterations occurred in tumors whereas they seem to have a pro-inflammatory role in malignant
11 ascites. The correlation of TApDC with poor outcome confirms their participation in immune
12 tolerance. Likewise, identifying molecular pathways implicated in the inhibition of IFN- α
13 production by TApDC will help to develop targeted therapies reversing the deleterious role of
14 TApDC in the context of OC.

15

pDC induce immune tolerance in ovarian cancer

1

2 **Acknowledgements**

3 The authors are grateful to the ovarian cancer patients who consented to participate to this
4 study and to the medical staff from Centre Leon Berard (CLB). We thank Dr Philippe Gabelle
5 from Clinique des Eaux-Clares, Grenoble and Dr Philippe Bouchard from Clinique des
6 Cèdres, Grenoble for their active participation in this translational research program. We also
7 thank Dr Philippe Cassier from CLB for his editorial assistance.

8 Grant support: This work was supported by institutional grant from Comité départemental du
9 Puy-de-Dôme de la Ligue nationale contre le cancer. S-I L-G is a recipient of a grant Soutien à
10 la formation à la recherche translationnelle en cancérologie from Institut National du cancer
11 (INCa), France

12

13 **Conflict of interest**

14 The authors have no conflict of interest to disclose.

15

pDC induce immune tolerance in ovarian cancer

1 **References**

- 2 1. Society, A. C. Cancer Facts&Figures 2007. Atlanta: American Cancer Society, 2007.
- 3 2. Chan, J. K., Zhang, M., Hu, J. M., Shin, J. Y., Osann, K., and Kapp, D. S. Racial
4 disparities in surgical treatment and survival of epithelial ovarian cancer in United
5 States. *J Surg Oncol*, *97*: 103-107, 2008.
- 6 3. Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W.,
7 and Schmitz, J. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of
8 dendritic cells in human peripheral blood. *J Immunol*, *165*: 6037-6046, 2000.
- 9 4. Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A.,
10 and Colonna, M. Plasmacytoid monocytes migrate to inflamed lymph nodes and
11 produce large amounts of type I interferon. *Nat Med*, *5*: 919-923, 1999.
- 12 5. Yoneyama, H., Matsuno, K., Zhang, Y., Nishiwaki, T., Kitabatake, M., Ueha, S.,
13 Narumi, S., Morikawa, S., Ezaki, T., Lu, B., Gerard, C., Ishikawa, S., and Matsushima,
14 K. Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed
15 lymph nodes through high endothelial venules. *Int Immunol*, *16*: 915-928, 2004.
- 16 6. Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S.,
17 Antonenko, S., and Liu, Y. J. The nature of the principal type 1 interferon-producing
18 cells in human blood. *Science*, *284*: 1835-1837, 1999.
- 19 7. Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid
20 dendritic cell precursors. *Annu Rev Immunol*, *23*: 275-306, 2005.
- 21 8. Kamath, A. T., Sheasby, C. E., and Tough, D. F. Dendritic cells and NK cells stimulate
22 bystander T cell activation in response to TLR agonists through secretion of IFN-alpha
23 beta and IFN-gamma. *J Immunol*, *174*: 767-776, 2005.
- 24 9. Jego, G., Palucka, A. K., Blanck, J. P., Chalouni, C., Pascual, V., and Banchereau, J.
25 Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon
26 and interleukin 6. *Immunity*, *19*: 225-234, 2003.
- 27 10. Ochando, J. C., Homma, C., Yang, Y., Hidalgo, A., Garin, A., Tacke, F., Angeli, V., Li,
28 Y., Boros, P., Ding, Y., Jessberger, R., Trinchieri, G., Lira, S. A., Randolph, G. J., and
29 Bromberg, J. S. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance
30 to vascularized grafts. *Nat Immunol*, *7*: 652-662, 2006.
- 31 11. Goubier, A., Dubois, B., Gheit, H., Joubert, G., Villard-Truc, F., Asselin-Paturel, C.,
32 Trinchieri, G., and Kaiserlian, D. Plasmacytoid dendritic cells mediate oral tolerance.
33 *Immunity*, *29*: 464-475, 2008.
- 34 12. de Heer, H. J., Hammad, H., Soullie, T., Hijdra, D., Vos, N., Willart, M. A.,
35 Hoogsteden, H. C., and Lambrecht, B. N. Essential role of lung plasmacytoid dendritic
36 cells in preventing asthmatic reactions to harmless inhaled antigen. *J Exp Med*, *200*: 89-
37 98, 2004.
- 38 13. Sisirak V, G. M., Renaudineau S, Menetrier-Caux C, Asford C, Banchereau J, Palucka
39 AK, Blay JY, Caux C, Bendriss-Vermare N Breast carcinoma environment inhibits
40 human plasmacytoid dendritic cells functions. In the 10th international symposium on
41 dendritic cells(kobe, japan), 2008.
- 42 14. Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei,
43 S., Krzysiek, R., Durand-Gasselien, I., Gordon, A., Pustilnik, T., Curiel, D. T., Galanaud,
44 P., Capron, F., Emilie, D., and Curiel, T. J. Stromal-derived factor-1 in human tumors
45 recruits and alters the function of plasmacytoid precursor dendritic cells. *Nat Med*, *7*:
46 1339-1346, 2001.
- 47 15. Vermi, W., Bonocchi, R., Facchetti, F., Bianchi, D., Sozzani, S., Festa, S., Berenzi, A.,
48 Cella, M., and Colonna, M. Recruitment of immature plasmacytoid dendritic cells

pDC induce immune tolerance in ovarian cancer

- 1 (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous
2 melanomas. *J Pathol*, *200*: 255-268, 2003.
- 3 16. Hartmann, E., Wollenberg, B., Rothenfusser, S., Wagner, M., Wellisch, D., Mack, B.,
4 Giese, T., Gires, O., Endres, S., and Hartmann, G. Identification and functional analysis
5 of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. *Cancer Res*,
6 *63*: 6478-6487, 2003.
- 7 17. Treilleux, I., Blay, J. Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T.,
8 Guastalla, J. P., Bremond, A., Goddard, S., Pin, J. J., Barthelemy-Dubois, C., and
9 Lebecque, S. Dendritic cell infiltration and prognosis of early stage breast cancer. *Clin*
10 *Cancer Res*, *10*: 7466-7474, 2004.
- 11 18. Tjomsland, V., Sandstrom, P., Spangeus, A., Messmer, D., Emilsson, J., Falkmer, U.,
12 Falkmer, S., Magnusson, K. E., Borch, K., and Larsson, M. Pancreatic adenocarcinoma
13 exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic
14 cells: an indicator of disease severity? *BMC Cancer*, *10*: 87.
- 15 19. Wertel, I., Polak, G., Bednarek, W., Barczynski, B., Rolinski, J., and Kotarski, J.
16 Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering
17 from ovarian cancer. *Cytometry B Clin Cytom*, *74*: 251-258, 2008.
- 18 20. Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M.,
19 Wei, S., Zou, L., Kryczek, I., Hoyle, G., Lackner, A., Carmeliet, P., and Zou, W.
20 Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer.
21 *Cancer Res*, *64*: 5535-5538, 2004.
- 22 21. Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A.,
23 and Zou, W. Plasmacytoid dendritic cells induce CD8⁺ regulatory T cells in human
24 ovarian carcinoma. *Cancer Res*, *65*: 5020-5026, 2005.
- 25 22. DR, C. Regression model and lifer tables (with discussion). *JR Stat Soc*, *34*: 187-220,
26 1972.
- 27 23. Olweus, J., BitMansour, A., Warnke, R., Thompson, P. A., Carballido, J., Picker, L. J.,
28 and Lund-Johansen, F. Dendritic cell ontogeny: a human dendritic cell lineage of
29 myeloid origin. *Proc Natl Acad Sci U S A*, *94*: 12551-12556, 1997.
- 30 24. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B.,
31 and Palucka, K. Immunobiology of dendritic cells. *Annu Rev Immunol*, *18*: 767-811,
32 2000.
- 33 25. du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., and Pfisterer,
34 J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a
35 combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials:
36 by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe
37 Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les
38 Etudes des Cancers de l'Ovaire (GINECO). *Cancer*, *115*: 1234-1244, 2009.
- 39 26. Shi, Y., Evans, J. E., and Rock, K. L. Molecular identification of a danger signal that
40 alerts the immune system to dying cells. *Nature*, *425*: 516-521, 2003.
- 41 27. Colonna, M., Trinchieri, G., and Liu, Y. J. Plasmacytoid dendritic cells in immunity.
42 *Nat Immunol*, *5*: 1219-1226, 2004.
- 43 28. Iwasaki, A. and Medzhitov, R. Toll-like receptor control of the adaptive immune
44 responses. *Nat Immunol*, *5*: 987-995, 2004.
- 45 29. Bekeredian-Ding, I., Schafer, M., Hartmann, E., Pries, R., Parcina, M., Schneider, P.,
46 Giese, T., Endres, S., Wollenberg, B., and Hartmann, G. Tumour-derived prostaglandin
47 E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-
48 derived interferon-alpha. *Immunology*, *128*: 439-450, 2009.
- 49 30. Dolganiuc, A., Chang, S., Kodys, K., Mandrekar, P., Bakis, G., Cormier, M., and
50 Szabo, G. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated

pDC induce immune tolerance in ovarian cancer

- 1 mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV
2 infection. *J Immunol*, *177*: 6758-6768, 2006.
- 3 31. Palucka, A. K., Blanck, J. P., Bennett, L., Pascual, V., and Banchereau, J. Cross-
4 regulation of TNF and IFN-alpha in autoimmune diseases. *Proc Natl Acad Sci U S A*,
5 *102*: 3372-3377, 2005.
- 6 32. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z. K.,
7 Endres, S., Krieg, A. M., and Hartmann, G. Identification of CpG oligonucleotide
8 sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. *Eur J*
9 *Immunol*, *31*: 2154-2163, 2001.
- 10 33. Domschke, C., Schuetz, F., Ge, Y., Seibel, T., Falk, C., Brors, B., Vlodaysky, I.,
11 Sommerfeldt, N., Sinn, H. P., Kuhnle, M. C., Schneeweiss, A., Scharf, A., Sohn, C.,
12 Schirmmacher, V., Moldenhauer, G., Momburg, F., and Beckhove, P. Intratumoral
13 cytokines and tumor cell biology determine spontaneous breast cancer-specific immune
14 responses and their correlation to prognosis. *Cancer Res*, *69*: 8420-8428, 2009.
- 15 34. Contractor, N., Louten, J., Kim, L., Biron, C. A., and Kelsall, B. L. Cutting edge:
16 Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I
17 interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a
18 unique mucosal pDC phenotype. *J Immunol*, *179*: 2690-2694, 2007.
- 19 35. Li, L., Liu, S., Zhang, T., Pan, W., Yang, X., and Cao, X. Splenic stromal
20 microenvironment negatively regulates virus-activated plasmacytoid dendritic cells
21 through TGF-beta. *J Immunol*, *180*: 2951-2956, 2008.
- 22 36. Epstein, L. B., Shen, J. T., Abele, J. S., and Reese, C. C. Sensitivity of human ovarian
23 carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-
24 solid agar technique. *Ann N Y Acad Sci*, *350*: 228-244, 1980.
- 25 37. Einhorn, N., Cantell, K., Einhorn, S., and Strander, H. Human leukocyte interferon
26 therapy for advanced ovarian carcinoma. *Am J Clin Oncol*, *5*: 167-172, 1982.
- 27 38. Berek, J. S., Markman, M., Blessing, J. A., Kucera, P. R., Nelson, B. E., Anderson, B.,
28 and Hanjani, P. Intraperitoneal alpha-interferon alternating with cisplatin in residual
29 ovarian carcinoma: a phase II Gynecologic Oncology Group study. *Gynecol Oncol*, *74*:
30 48-52, 1999.
- 31 39. Berek, J. S., Markman, M., Stonebraker, B., Lentz, S. S., Adelson, M. D., DeGeest, K.,
32 and Moore, D. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II
33 gynecologic oncology group study. *Gynecol Oncol*, *75*: 10-14, 1999.
- 34 40. Dunn, G. P., Koebel, C. M., and Schreiber, R. D. Interferons, immunity and cancer
35 immunoediting. *Nat Rev Immunol*, *6*: 836-848, 2006.
- 36 41. Moserle, L., Indraccolo, S., Ghisi, M., Frasson, C., Fortunato, E., Canevari, S., Miotti,
37 S., Tosello, V., Zamarchi, R., Corradin, A., Minuzzo, S., Rossi, E., Basso, G., and
38 Amadori, A. The side population of ovarian cancer cells is a primary target of IFN-
39 alpha antitumor effects. *Cancer Res*, *68*: 5658-5668, 2008.
- 40 42. Biron, C. A. Interferons alpha and beta as immune regulators--a new look. *Immunity*,
41 *14*: 661-664, 2001.
- 42 43. Robak, E., Smolewski, P., Wozniacka, A., Sysa-Jedrzejowska, A., and Robak, T.
43 Clinical significance of circulating dendritic cells in patients with systemic lupus
44 erythematosus. *Mediators Inflamm*, *13*: 171-180, 2004.
- 45 44. Pacanowski, J., Kahi, S., Baillet, M., Lebon, P., Deveau, C., Goujard, C., Meyer, L.,
46 Oksenhendler, E., Sinet, M., and Hosmalin, A. Reduced blood CD123+ (lymphoid) and
47 CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. *Blood*, *98*: 3016-
48 3021, 2001.

pDC induce immune tolerance in ovarian cancer

- 1 45. Soumelis, V., Scott, I., Gheyas, F., Bouhour, D., Cozon, G., Cotte, L., Huang, L., Levy,
2 J. A., and Liu, Y. J. Depletion of circulating natural type 1 interferon-producing cells in
3 HIV-infected AIDS patients. *Blood*, 98: 906-912, 2001.
- 4 46. Barron, M. A., Blyveis, N., Palmer, B. E., MaWhinney, S., and Wilson, C. C. Influence
5 of plasma viremia on defects in number and immunophenotype of blood dendritic cell
6 subsets in human immunodeficiency virus 1-infected individuals. *J Infect Dis*, 187: 26-
7 37, 2003.
- 8 47. Donaghy, H., Pozniak, A., Gazzard, B., Qazi, N., Gilmour, J., Gotch, F., and Patterson,
9 S. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in
10 patients with HIV-1 infection correlates with HIV-1 RNA virus load. *Blood*, 98: 2574-
11 2576, 2001.
- 12 48. Killian, M. S., Fujimura, S. H., Hecht, F. M., and Levy, J. A. Similar changes in
13 plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and
14 treatment. *Aids*, 20: 1247-1252, 2006.
- 15 49. Schmidt, B., Fujimura, S. H., Martin, J. N., and Levy, J. A. Variations in plasmacytoid
16 dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects
17 on and off antiretroviral therapy. *J Clin Immunol*, 26: 55-64, 2006.
- 18 50. Feldman, S., Stein, D., Amrute, S., Denny, T., Garcia, Z., Kloser, P., Sun, Y.,
19 Megjugorac, N., and Fitzgerald-Bocarsly, P. Decreased interferon-alpha production in
20 HIV-infected patients correlates with numerical and functional deficiencies in
21 circulating type 2 dendritic cell precursors. *Clin Immunol*, 101: 201-210, 2001.
- 22
- 23
- 24

pDC induce immune tolerance in ovarian cancer

1 **Figures legends**

2 **Figure 1. Distribution and frequency of CD4⁺ BDCA2⁺ CD123⁺ plasmacytoid dendritic**
3 **cells (pDC) and Lin⁻CD4⁺CD11c⁺ myeloid dendritic cells (mDC) obtained by FACS**

4 **analysis in biological samples.** Mononuclear cells (MNC) from freshly untreated ovarian
5 cancers (OC), malignant ascites, and peripheral blood from OC patients (P) and healthy donors
6 (HD) were prepared. Box plot set of pDC and mDC levels determined as a percentage among
7 total MNC. *P* values were derived from Mann-Whitney test or Student test for each
8 comparison. (A) and (B) PDC and mDC levels among MNC in blood, ascite, and tumors of OC
9 patients and blood of HD (C) and (D) PDC and mDC levels among PBMC in HD and OC
10 patients according to the stage of the disease. (E) and (F) PDC and mDC levels among PBMC
11 in OC patients during therapy and comparison with HD. + : extremes; ○ : outlier. * :< 0.05;
12 **:<10⁻²; ***:<10⁻³. CR=complete remission

13

14 **Figure 2. Tumors highly infiltrated by pDC showed early relapse.** Progression-free survival

15 (PFS) rates were calculated using Kaplan-Meier method and compared using Log-Rank test.
16 (A) Box plot set showing Tumor-Associated pDC (TApDC) levels in patients in complete
17 remission (CR) and those with progressive disease after a median follow-up of 14 months. (B),
18 (C), (D), and (E) PFS of patients with the highest tertile (33rd percentile) frequency of TApDC
19 (≥0.1 %), ascite pDC (≥ 1%), TAmDC (≥0.02%) and ascite mDC (≥0.13%) compared to all
20 others. HR: Hazard Ratio, *** :< 10⁻³

21

22 **Figure 3. TApDC isolated from ovarian tumors display a partially activated phenotype.**

23 Three-color flow cytometry analysis was used to assess the expression of CD40 and CD86 on
24 CD4⁺CD123⁺ pDC from blood, ascites, and tumors from 17 OC patients. Statistical analysis

pDC induce immune tolerance in ovarian cancer

1 was performed using Mann-Whitney test. Values are expressed as Mean Fluorescence Intensity
2 (MFI) minus FMO control. + : extremes; ○ : outlier. * :< 0.05; ** :< 10⁻².

3

4 **Figure 4. TApDC and ascite pDC acquire a fully mature phenotype after TLR ligands**
5 **activation *in vitro*.** Highly purified TApDC (n=5), ascites pDC (n=5), and HD blood pDC
6 (n=2) were cultured with IL-3 (20 ng/ml), inactivated flu (Influenza) virus (100 HAU/ml), and
7 CpG-A (5 mg/ml) for 40 h. Activation of pDC was monitored by analyzing CD40 and CD86
8 expression by flow cytometry. Data are representative of two or five independent experiments
9 and MFI values of total cells are indicated in each histogram.

10

11 **Figure 5. TApDC prime allogeneic naïve CD4⁺ T cells and induce IL-10 T cell response.**
12 (A) Spearman rank correlations between the proportion of CD4⁺BDCA2⁺CD123⁺ pDC and
13 CD3⁺CD4⁺ T lymphocytes in ovarian tumors. (B) FACS-sorted TApDC and ascites pDC were
14 cultured with IL-3 (20 ng/ml) for 24 h and then incubated at graded doses with naive allogeneic
15 CD4⁺CD45RA⁺ T cells for five days. T cell proliferation was determined by 3H thymidine
16 incorporation (mean and s.e.m (error bars) of triplicate cultures). (C) Culture supernatants were
17 collected and IL-10 and IFN-γ were analyzed by ELISA. Data are one of two independent
18 experiments. * :< 0.05. TA: Tumor-Associated.

19

20 **Figure 6. TApDC are inhibited for their IFN-α production following TLR ligands**
21 **stimulation.** (A) and (B) FACS-sorted TApDC, ascites pDC, and blood pDC from healthy
22 donors (HD) were cultured with inactivated flu virus (100 HAU/ml) and CpG-A (5 μg/ml) for
23 24 h. IFN-α production in culture supernatants was determined by ELISA. Results were
24 standardized by calculating the production of IFN-α for 1x10⁵ pDC for each sample. (C) and
25 (D) Total MNC (1x10⁶ cells/well) from blood, ascites, and tumors of the same patients (n=6)

pDC induce immune tolerance in ovarian cancer

1 and from blood of healthy donors (HD) (n=8) were activated in duplicate with TLR-7 (flu) and
2 9 (CpG-A) ligands for 18 hours in 24-well tissue culture plates. IFN- α production was
3 measured by ELISA and standardized to the percentage of pDC contained in each sample as
4 determined by FACS analysis. The production of IFN- α was adjusted to 1×10^5 pDC. Median
5 values are represented by horizontal lines in each series.

6

7 **Figure 7. Ovarian tumor microenvironment inhibits IFN- α production by healthy pDC**
8 **through TGF- β and TNF- α cooperation.** Supernatants of single-cell suspensions from
9 ovarian tumors (TUMSN) were collected after 48 h and frozen. (A) Purified blood pDC from
10 HD were preincubated with 20 ng/ml IL-3 either alone or with 25% of TUMSN derived from
11 five different OC patients for 16 h and then activated or not for another 24 h with inactivated fu
12 virus (100 HAU/ml) or CpG-A (5 μ g/ml). After 40 h, the production of IFN- α and IP-10 was
13 measured by ELISA. No IFN- α was detected in media conditions (no TLR activation) and IP-
14 10 was detected in some ovarian tumor-derived supernatants at low levels. (B) Purified tonsil
15 pDC were preincubated with IL-3 either alone or in combination with 25% of ovarian TUMSN
16 in the presence or absence of specific control isotype antibodies, anti-TNF- α , anti-IL-10
17 Receptor, and anti-TGF- β blocking antibodies (10 μ g/ml) for 16 h. Flu virus was then added
18 for another 24 h. IFN- α was measured in culture supernatants by ELISA. Data are expressed as
19 mean \pm SD and are representative of three independent experiments.

20

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7

A



B



Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer

Sana Intidhar Labidi-Galy, Vanja Sisirak, Pierre Meeus, et al.

Cancer Res Published OnlineFirst June 22, 2011.

Updated version	Access the most recent version of this article at: doi: 10.1158/0008-5472.CAN-11-0367
Supplementary Material	Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/06/22/0008-5472.CAN-11-0367.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/early/2011/06/21/0008-5472.CAN-11-0367>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.